Pancreatic cancer
Conditions
Interventions
Intratumoral administration of Surv.m-CRA-1 Frequency of administration: once a week, three times in total Dose: 1xE+11 viral particles
Sponsors
Kagoshima University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: The patients with pancreatic tumors must meet the following eligibility criteria: 1) Diagnosed histologically with pancreatic ductal carcinoma. 2) Diagnosed with unresectable pancreatic cancer because of metastasis and/or vascular invasion. 3) Primary standard treatment for unresectable pancreatic cancer failed. If a patient who received radiation or chemoradiation therapy for locally advanced pancreatic cancer is judged to have failed the primary treatment due to metastasis without progression of pancreatic cancer or drug-induced adverse events, the period after radiation must be at least one month. 4) The long and short axes and height of the pancreatic lesion can be measured by computed tomography, and the investigational agent can be administered to the lesion. 5) >= 20 years old. 6) ECOG performance status (PS) is 0-2. 7) The overall survival is expected to exceed three months. 8) Main organ functions are maintained (according to the latest blood test performed within two weeks before registration): Hb >= 7 g/dL WBC >= 2,000/microL Plt >= 50,000/microL AST (GOT) <= 100 IU/L ALT (GPT) <= 100 IU/L T-bil <= 3.0 mg/dL Cr <= 2.0 mg/dL 9) Agrees to not become pregnant. 10) Gives their written consent to participate in the clinical trial.
Exclusion criteria
Exclusion criteria: 1) Patients with the following complications: Severe heart disease, severe respiratory disease, severe digestive disease, severe liver disease, uncontrolled diabetes, and infection requiring continuous treatment 2) Patients with a history of penicillin or allergy to pigs or cattle (including milk). 3) Patients with a disease that requires the administration of systemic immunosuppressants or steroids. 4) For patients judged to have failed the primary therapy of radiation or chemoradiation, the interval after the therapy is <= 1 month (patients are still eligible if the reason for primary therapy failure is progression of pancreatic cancer). 5) Patients with other currently active cancers (patients are still eligible if the other cancers are basal cell carcinoma, carcinoma in situ, superficial bladder cancer, or malignancies without metastasis or recurrence for more than five years and have been treated appropriately) 6) Patients with an uncontrollable fever or pain due to the tumor. 7) Patients with a history of gastroduodenal surgery or gastroduodenal stricture. 8) Patients who are pregnant, breast-feeding, or have a positive pregnancy test within one year after menopause. 9) Patients who received any other unapproved drug within four weeks before giving their consent. 10) Patients deemed inappropriate to include in the trial by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse event, response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum level of adenovirus, adenovirus excretion, antibody level of adenovirus, cytokine levels, rate of tumor size reduction, histological assessment, progression-free survival, overall survival | — |
Countries
Japan
Contacts
Public ContactToshitaka Futagawa
Kagoshima University hospital Division of Clinical Trial, Clinical Research Management Center
Outcome results
None listed